Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome;Influencia de los polimorfismos de CYP2C19 en la reactividad plaquetaria y el pronóstico en una población no seleccionada de pacientes con síndrome coronario agudo sin elevación del ST

Revista Espanola de Cardiologia

Volumn 65, Issue 3, 2012, Pages 219-226

  Tello Montoliu, Antonio ^a   Jover, Eva ^a   Marín, Francisco ^a,b   Bernal, Agustina ^b,c   Lozano, María L ^b,c   Sánchez Vega, Beatriz ^b,c   Pastor, Francisco J ^a,b   Hurtado, José A ^a,b   Valdés, Mariano ^a,b   Vicente, Vicente ^b,c   Rivera, José ^b,c  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

Author keywords

CYP2C19; Platelet aggregation inhibitors; Platelets; Unstable angina

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; PHOSPHOPROTEIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ACUTE CORONARY SYNDROME; ALLELE; CONTROLLED STUDY; CORONARY STENT; FLOW CYTOMETRY; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; NON ST ELEVATION ACUTE CORONARY SYNDROME; PROGNOSIS; PROTEIN PHOSPHORYLATION; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION; UNSPECIFIED SIDE EFFECT;

EID: 84857501835     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2011.07.013     Document Type: Article

References (34)

1. M. Kazui, Y. Nishiya, T. Ishizuka, K. Hagihara, N.A. Farid, and O. Okazaki Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
2. H.J. Bouman, A.M. Harmsze, J.W. Van Werkum, N.J. Breet, T.O. Bergmeijer, and H. Ten Cate Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting Heart 97 2011 1239 1244
3. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Méneveau French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
4. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
5. J.L. Mega, T. Simon, J.P. Collet, J.L. Anderson, E.M. Antman, and K. Bliden Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis JAMA 304 2010 1821 1830
6. D. Sibbing, W. Koch, D. Gebhard, T. Schuster, S. Braun, and J. Stegherr Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 481 483
7. G. Paré, S.R. Mehta, S. Yusuf, S.S. Anand, S.J. Connolly, and J. Hirsh Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med 363 2010 1704 1714
8. J.L. Anderson, C.D. Adams, E.M. Antman, C.R. Bridges, R.M. Califf, and D.E. Casey Jr. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Circulation 116 2007 e148 e304
9. E.M. Antman, M. Cohen, P.J. Bernink, C.H. McCabe, T. Horacek, and G. Papuchis The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making JAMA 284 2000 835 842 (Pubitemid 30643610)
10. M. Cattaneo, A. Lecchi, M.L. Zighetti, and F. Lussana Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count Haematologica 92 2007 694 697 (Pubitemid 350144275)
11. B. Aleil, C. Ravanat, J.P. Cazenave, G. Rochoux, A. Heitz, and C. Gachet Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases J Thromb Haemost 3 2005 85 92 (Pubitemid 41647119)
12. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, R. Becker Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
13. J. Rivera, M.L. Lozano, L. Navarro-Núñez, and V. Vicente Platelet receptors and signaling in the dynamics of thrombus formation Haematologica 94 2009 700 711
14. A.D. Michelson Methods for the measurement of platelet function Am J Cardiol 103 Suppl 3 2009 A20 A26
15. M.J. Price, and C.M. Barker Functional testing methods for the antiplatelet effect of P2Y(12) receptor antagonists Biomark Med 5 2011 43 51
16. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thromb Res. 2011 May 26 [Epub ahead of print].
17. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, J.R. Walker, and T. Simon Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 2010 1312 1319
18. L. Wallentin, S. James, R.F. Storey, M. Armstrong, B.J. Barratt, J. Horrow PLATO investigators Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
19. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, and R.B. Horenstein Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
20. E. Braunwald, D. Angiolillo, E. Bates, P.B. Berger, D. Bhatt, and C.P. Cannon The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention Clin Cardiol 31 3 Suppl 1 2008 17 20
21. W. Hochholzer, D. Trenk, M.F. Fromm, C.M. Valina, C. Stratz, and H.P. Bestehorn Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
22. J.L. Ferreiro, D. Sibbing, and D.J. Angiolillo Platelet function testing and risk of bleeding complications Thromb Haemost 103 2010 1128 1135
23. K.A. Tiroch, D. Sibbing, W. Koch, T. Roosen-Runge, J. Mehilli, and A. Schömig Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events Am Heart J 160 2010 506 512
24. J.L. Ferreiro, and D.J. Angiolillo Clopidogrel response variability: current status and future directions Thromb Haemost 102 2009 7 14
25. 12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras Rev Esp Cardiol 63 2010 60 76
26. L. Bonello, S. Armero, O. Ait Mokhtar, J. Mancini, P. Aldebert, and N. Saut Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism J Am Coll Cardiol 56 2010 1630 1636
27. C.D. Anderson, A. Biffi, S.M. Greenberg, and J. Rosand Personalized approaches to clopidogrel therapy: are we there yet? Stroke 41 2010 2997 3002
28. D.J. Angiolillo Variability in responsiveness to oral antiplatelet therapy Am J Cardiol 103 Suppl 3 2009 A27 A34
29. C. Múñoz, E. Jover, D. Hernández-Romero, D. Saura, M. Valdés, and G.Y.H. Lip Interactions between clopidogrel and proton pump inhibitors: a review of evidence Curr Med Chem 18 2011 2386 2400
30. J.S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, and C. Goyenvalle Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247 (Pubitemid 44497506)
31. P. Fontana, J.S. Hulot, M.P. De, and P. Gaussem Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects J Thromb Haemost 5 2007 2153 2155 (Pubitemid 47450038)
32. C. Frere, T. Cuisset, P.E. Morange, J. Quilici, L. Camoin-Jau, and N. Saut Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome Am J Cardiol 101 2008 1088 1093
33. T. Geisler, B. Bigalke, and M. Schwab CYP2C19 genotype and outcomes of clopidogrel treatment N Engl J Med 364 2011 481 482
34. 12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease Thromb Haemost 105 2011 730 732